STRATA Skin Sciences, Inc. · OTC:SSKN
STRATA Skin Sciences — Investor Presentation (February 2019)
35 slides from STRATA Skin Sciences's investor presentation, Feb 26, 2019
Slide 1: February 2019 Investor Presentation
February 2019 Investor Presentation Driving Value to Dermatology Partners Matching Patients and Clinics
Slide 2: Safe Harbor Statement
This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking s
Slide 3: STRATA Investment Highlights
STRATA Investment Highlights Seasoned Management Team – with Deep Domain KnowledgeDr. Dolev Rafaeli, CEO returns with the Accelmed transaction Excimer Laser Technology for Dermatology IndicationsPsoriasis, Vitiligo, Eczema, Atopic Dermatitis and Leukoderma Large Market Opportunity Over 35 Million av
Slide 4: XTRAC Revenue Growth Strategy
XTRAC Revenue Growth Strategy 8n6 Protocol Treatment *RDX – Reimbursement Database XTRAC (proprietary system) REOCCURRENCE DTC ADVERTISING ASSIGNING A DOCTOR PARTNER PATIENTAPPOINTMENT TREATMENT WIN WIN WIN DOCTOR PATIENT STRATA (AND PAYER) INTEREST CREATION IN-HOUSE CALL CENTER INSURANCE ADVOCACY V
Slide 5: XTRAC DTC Advertising
XTRAC DTC Advertising Vary ye Psori: © acatasa 300-874-8762 Usektrac.com XTRAC = STRATA
Slide 6: Lead Generation is a Business Driver
Lead Generation is a Business Driver Patient leads in one quarterLeads turn into appointmentsAppointments lead to XTRAC partner revenueOther revenue for the partner clinicRevenue for STRATA 6 NYC, NJ, Long Island
Slide 7: DTC Results – Lead generation by quarter 2017 and 2018
DTC Results – Lead generation – by quarter 2017 and 2018 7
Slide 8: The Market Opportunity
The Market Opportunity XTRAC cleared in four indications PsoriasisVitiligoEczema and Atopic DermatitisLeukodermaOver 35 million domestic patients3 CPT codes ($150 - $250 based on BSA)$170 average reimbursement rate per treatmentClinical Protocol – 6.2 treatments to PASI 75 Average of 23 treatments p
Slide 9: Excimer Laser Technology - XTRAC / VTRAC
Excimer Laser Technology - XTRAC® / VTRAC® TechnologyXTRAC excimer laser uses highly targeted (308nm) beam of UVB light to treat affected skin area without damaging surrounding tissueVTRAC is a lamp based 308nm laserTreatment avoids side effects, cost of biologics and messy topicalsTreatments are sa
Slide 10: How XTRAC Works - Psoriasis
How XTRAC Works - Psoriasis After 4 tx After 2 tx Baseline Beam of UVB light applied to the affected area UVB light induces apoptosis of the keratinocytes and T cells in the dermis Promotes immunosuppression Induces alterations in cytokine profile 140+ peer reviewed published clinical studies 10
Slide 11: How XTRAC Works - Vitiligo
How XTRAC Works - Vitiligo 11 Long-term skin condition characterized by patches of skin losing its pigment Disease is believed to be due to genetic susceptibility where the autoimmune disease is then triggeredPotentially the immune system is attacking and destroying melanocytes of the skinLife-alter
Slide 12: Domestic Market: Installed Base Overview
Domestic Market: Installed Base Overview 750 Partner XTRAC 138 sold XTRAC 4 Regions 22 Sales Territories 15 Field Service Techs In-house call center to qualify leadsOnly one competitor in U.S. 12 Territories color coded
Slide 13: International Market: Installed Base
International Market: Installed Base OUS sales are through distribution with no current recurring revenue model appliedMajor Markets – China, Japan, Saudi Arabia, South KoreaInsurance covered in most marketsUsage/device higher than domestic market – untapped potential in U.S.Over 1,200 OUS devices s
Slide 14: Turnaround Strategy
Turnaround Strategy DOMESTIC MARKET OUS MARKETS Enhance technology offeringExpand geographical reach in certain markets Rebuild XTRAC value proposition for partner dermatologistsDTC is a revenue driver: Online and offline advertisement, in-house call centerPatient Communication: For both referrals a
Slide 15: Transformative Transaction – Back to the Future
Transformative Transaction – “Back to the Future” Based on STRATA 10-k Annual Report; Dec 31, 2017 and quarterly filings* STRATA bought XTRAC business from PhotoMedex in 2015 15 Note the numbers prior to Jan 1, 2018 do not reflect adjustments for the adoption Of ASC 606
Slide 16: Media Spend to Recurring XTRAC Treatment Revenue: The Opportunity
Media Spend to Recurring XTRAC Treatment Revenue: The Opportunity Based on STRATA and PhotoMedex Investor Presentations* STRATA bought XTRAC business from PhotoMedex in 2015 16
Slide 17: Financial Metrics
Financial Metrics (in thousands except for Average Recurring Revenue per Consigned Systems and Systems Placed under Recurring Revenue Model) Q12017__Q22017__Q32017 042017 Qi2018 _Q2 2018 Dermatology recurring procedures revenue $5556 $ 5971 $ 5525/$ 5588 $ 4498 $ 5,167 Dermatology procedures equipme
Slide 18: Comebacks – Important path to growing recurring revenue
Comebacks – Important path to growing recurring revenue Existing excimer laser-sites: comeback drives revenue quicker 18
Slide 19: Changing Dynamic in Healthcare – Clinic Roll-Ups
Changing Dynamic in Healthcare – Clinic Roll-Ups* Mapped 1,570 PE and private national group roll ups 58 different groups identifiedXTRAC placement penetration 151** – 9.5% - Huge OpportunityAugust 20, 2018 – Company announces “Strategic Agreement with a Large Private Equity Backed Group of Dermatol
Slide 20: Current Clinical Protocol: 8N6 Protocol
Current Clinical Protocol For Optimal Patient Outcomes: 8N6 Protocol 01 Twice a week: Minimum 8 visits in 6 weeks 02 Starting dose of at least 300 mj 03 Increase Dose over Time 04 Patient Returns: At least 8 visits per patient 05 …and management of the database to track results 20
Slide 21: Maximizing Dermatologist Partner Clinical Revenue
Maximizing Dermatologist Partner Clinical Revenue Data collected directly from the lasers demonstrates the importance of following treatment guidelines Revenue = # of lasers x # of treatments/pt x # patients x cost/tx x recurrence factor 21
Slide 22: Optimal Therapeutic Dose (OTD) – 510(k) Received
Optimal Therapeutic Dose (“OTD”) – 510(k) Received August/2018The Path to Optimal Clinical Outcomes and Patient Retention MECHANISMTip applies 4 simultaneous doses of energy to the patient’s plaque PURPOSETo minimize number of treatments to clearance USEDose allows provider to determine blister thre
Slide 23: Recent news: OTD Clinical Study
Recent news OTD Clinical Study92% of the included participants responded to treatment by achieving a reduction in mPASI score of 75% or moreCompared to current average of 16-20 treatments with NB-UVB 308nm devices, OTD treatment produced statistically significant mPASI improvement by the second trea
Slide 24: Strong Leadership Team
Strong Leadership Team 24 Dr. Uri Geiger Chairman of the Board Dr. Dolev Rafaeli Chief Executive Officer Matthew C. Hill Chief Financial Officer Dr. Daniel Siegel Consultant
Slide 25: XTRAC used by leading teaching institutions
XTRAC used by leading teaching institutions
Slide 26: Recent Financial Highlights
Recent Financial Highlights Q2Q3 26 Total Revenue $7.5 million +17% versus Q1 2018 Recurring XTRAC Revenue $5.2 million +15% versus Q1 2018 Gross Margin 54% +5% versus Q1 2018 Dermatology Recurring Procedures Revenue Margin 64% +7% versus Q1 2018 Total Revenue $7.9 million +8% versus Q3 2017 Recurri
Slide 27: Financial Profile
Financial Profile Shares and Share Equivalents – Market cap*- $109M (As of Feb 19, 2019) * On an as converted basis of the convertible preferred stock** Does not include 2.4M warrants with a weighted average exercise price of $5.22 as of September 30, 2018 of which 1.6M expire in the first 7 months
Slide 28: STRATA Investment Highlights
STRATA Investment Highlights Seasoned Management Team – with Deep Domain KnowledgeDr. Dolev Rafaeli, CEO returns with the Accelmed transaction Excimer Laser Technology for Dermatology IndicationsPsoriasis, Vitiligo, Eczema, Atopic Dermatitis and Leukoderma Large Market Opportunity Over 35 Million av
Slide 29: February 2019 Driving Value to Dermatology Partners
February 2019 Investor Presentation Driving Value to Dermatology Partners Matching Patients and Clinics
Slide 30: Appendix
Appendix 30
Slide 31: XTRAC is to excimer what Xerox is to photocopy
XTRAC is to excimer what Xerox is to photocopy Over 150 peer-reviewed published clinical-studiesMultiple academic institutes in U.S. use XTRAC Over 2,000 device installed base worldwideOver 1000 dermatology practices in the U.S have XTRAC providing device access to over 3,000 dermatology providers O
Slide 32: Multicenter Psoriasis Study and Sample Clinical Studies
Multicenter Psoriasis Study1 Scalp Study3 124 patients were enrolled and 80 completed the protocol. 72% achieved at least 75% clearing in an average of 6.2 treatments. 84% of patients reached improvement of 75% or better after 10 or fewer treatments. 50% of patients reached improvement of 90% or bet
Slide 33: Continuous technology investment and business growth
Continuous technology investment and business growth 510 (K) FDA Approval AL-7000 Ultra Velocity 400 Velocity 700 Velocity 7 Series S3 2000 2005 2008 2010 2014 2018 CPT code Approval DTC platform creation 510 (K) FDA Approval (MMD)* Full Insurance Reimbursement 2012 *MMD tip is a diagnostic accessor
Slide 34: Patient Rebate Program
Patient Rebate Program Up to $500 Toward Out-of-Pocket Costs www.xtrachelps.com
Slide 35: Practice development program
Practice development program In Office Patient Education Materials for psoriasis, vitiligo & atopic dermatitis:Patient BrochuresCounter CardsIn Office Branding“Patient-Directed” marketing initiative:Patient Education MailingsOutreach ProgramsEblasts
STRATA Skin Sciences — Investor Presentation (February 2019) on 6ix